{"schema_version":"secwatch.filing_event.v1","accession":"0001297184-22-000053","form_type":"8-K","ticker":"AMPH","cik":"0001297184","company_name":"Amphastar Pharmaceuticals, Inc.","filed_at":"2022-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.043901+00:00","generated_at":"2026-06-22T05:03:43.865120+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Amphastar Q3 revenue up 7% to $120.1M; GAAP EPS falls to $0.30 from $0.59 YoY","bullets":["Net revenues $120.1M for Q3 2022, up from $112.2M in Q3 2021 (7% growth).","GAAP diluted EPS $0.30 vs $0.59 prior year; adjusted non-GAAP EPS $0.38 vs $0.46.","Nine-month revenues $364.0M vs $316.9M; GAAP net income $57.5M vs $42.4M.","Growth cited from epinephrine, Primatene Mist, and glucagon sales.","No guidance issued; management optimistic about pipeline progress."],"urls":{"canonical":"https://secwatch.observer/filing/0001297184-22-000053","json":"https://secwatch.observer/filing/0001297184-22-000053.json","markdown":"https://secwatch.observer/filing/0001297184-22-000053.md","text":"https://secwatch.observer/filing/0001297184-22-000053.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/0001297184-22-000053-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/amph-20221107x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T05:03:43.865120+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d23236370784f7479759c7e2034d8066e97b0a39","claim":"Amphastar Pharmaceuticals, Inc. reported three months ended September 30, 2022 results: revenue $120.1 million, net income $15.9 million, EPS $0.30 per share.","evidence_excerpt":"in such a filing. ​ --- EX-99.1 (EX-99.1) --- ​ Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 20 22 ​ Reports Net Revenues of $120.1 Million for the Three Months Ended September 30, 2022 ​ RANCHO CUCAMONGA, CA – November 7, 2022 – Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) (“Amphastar” or the “Company”) today","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1297184/000129718422000053/0001297184-22-000053-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$120.1 million"},{"label":"Net income","value":"$15.9 million"},{"label":"EPS","value":"$0.30 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}